Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15134687 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| SCHEMBL3436800 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| Hydrochloric Acid SCHEMBL16195604 | 0.98 | CYP2D6 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| Hydrochloric Acid SCHEMBL31535515 | 0.98 | CYP2D6 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| Hydrochloric Acid SCHEMBL9582248 | 0.98 | CYP2D6 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| Hydrochloric Acid SCHEMBL31535360 | 0.98 | CYP2D6 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| SCHEMBL2917918 | 0.89 | CYP2D6 (0.36) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| Trifluoroacetic Acid SCHEMBL13518942 | 0.84 | PKM (0.37) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| SCHEMBL2921380 | 0.82 | CYP2D6 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| SCHEMBL2918065 | 0.82 | CHRNB4 (0.34) | SLC6A2SLC6A4SLC6A3CYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| CN-117157299-B | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| CN-1809557-A | Compound | ASTRAZENECA AB (SE) | 2006-07-26 | — | — | CN | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | SLC6A2 3642/4885SLC6A4 1980/4885SLC6A3 3044/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | SLC6A2 3559/4885SLC6A4 3724/4885SLC6A3 3910/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | SLC6A2 3753/4885SLC6A4 2607/4885SLC6A3 3980/4885 |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | HBZ, ZFX, WIZ | SLC6A2 4314/4885SLC6A4 3546/4885SLC6A3 3069/4885 |
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | SLC6A2 3054/4885SLC6A4 3133/4885SLC6A3 3108/4885 |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP11B2, SDHA, CYP3A43 | SLC6A2 3013/4885SLC6A4 3315/4885SLC6A3 3720/4885 |
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | SLC6A2 2629/4885SLC6A4 3221/4885SLC6A3 2910/4885 |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP4A11, CYP11B1, CYP2D6 | SLC6A2 413/4885SLC6A4 615/4885SLC6A3 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.